
Werewolf Therapeutics (HOWL) Stock Forecast & Price Target
Werewolf Therapeutics (HOWL) Analyst Ratings
Bulls say
Werewolf Therapeutics Inc. is showing significant progress in its clinical development pipeline, particularly with its WTX-330 and WTX-124 programs, which have demonstrated favorable safety profiles and promising anti-tumor activity in clinical and preclinical studies. The company's innovative PREDATOR platform enhances dosing flexibility and efficacy while mitigating systemic toxicity, which could lead to improved patient outcomes compared to traditional therapies. With continued advancements, Werewolf's technologies have the potential to expand beyond oncology into broader immune-mediated indications, positioning the company favorably within the biopharmaceutical sector.
Bears say
Werewolf Therapeutics Inc reported a significant increase in its net loss, posting $20.4 million, or $0.46 per share, in the fourth quarter of 2024, which is notably higher than the $12.0 million loss recorded in the same quarter of the previous year. Concerns arise regarding the potential challenges faced by its lead candidate, WTX-124, including the risks of clinical or regulatory setbacks and questions surrounding its safety, efficacy, and pharmacokinetic properties, which could impede its commercial viability. Furthermore, the financial outlook is overshadowed by the possibility that expansion opportunities might not be fully recognized in the company's overall valuation, raising doubts about its future revenue generation capabilities.
This aggregate rating is based on analysts' research of Werewolf Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Werewolf Therapeutics (HOWL) Analyst Forecast & Price Prediction
Start investing in Werewolf Therapeutics (HOWL)
Order type
Buy in
Order amount
Est. shares
0 shares